Copyright
©The Author(s) 2023.
World J Hepatol. Nov 27, 2023; 15(11): 1188-1195
Published online Nov 27, 2023. doi: 10.4254/wjh.v15.i11.1188
Published online Nov 27, 2023. doi: 10.4254/wjh.v15.i11.1188
Figure 1 Benefits and risks of ruxolitinib use in terms of opportunistic infections in myeloproliferative neoplasms.
MPNs: Myeloproliferative neoplasms; RUX: Ruxolitinib; HBVr: Hepatitis B virus reactivation; NK cells: Natural killer cells.
- Citation: Adesola AA, Cozma MA, Chen YF, Srichawla BS, Găman MA. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. World J Hepatol 2023; 15(11): 1188-1195
- URL: https://www.wjgnet.com/1948-5182/full/v15/i11/1188.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i11.1188